Literature DB >> 15937809

Neonatal short bowel syndrome: a cohort study.

Paul W Wales1, Nicole de Silva, Jae H Kim, Loreto Lecce, Amarpreet Sandhu, Aideen M Moore.   

Abstract

BACKGROUND: To date, our knowledge of morbidity and mortality in neonatal short bowel syndrome (SBS) is based on individual case series. Shortcomings of the published literature include long patient recruitment time, selection bias, variable SBS definitions, failure to account for gestational age, and incomplete follow-up. By applying more rigorous methodology, our aim was to determine outcomes of SBS neonates compared with a control group of neonates without SBS.
METHODS: A cohort study of all neonates with abdominal pathology requiring laparotomy between January 1, 1997, and December 31, 1998, with observation through July 1, 2001. Short bowel syndrome was defined as patients requiring parenteral nutrition for more than 42 days or residual small bowel length of less than 25% predicted by gestational age. Student's t test, Mann-Whitney U test, and chi2 were used where appropriate. Kaplan-Meier curves were used to determine cumulative survival. Covariates important in the development of SBS were examined using forward step-wise logistic regression.
RESULTS: There were 175 patients (with SBS = 40, without SBS = 135) with a mean gestational age of 30.7 +/- 4.6 weeks vs 35.9 +/- 4.8 weeks, respectively (P < .0005). The patients with SBS suffered significantly more morbidity than the group without SBS in all categories of investigation (surgical complications, septic events, central venous line complications, duration to adaptation and parenteral nutrition independence, cholestasis and liver failure, and duration of hospitalization). The case fatality rate was 37.5% in patients with SBS vs 13.3% in patients without SBS (P = .001). Most of the deaths were caused by liver failure or sepsis and occurred within 1 year from the date of surgery. Presence of an ileostomy (exp(B) = 12.29; P < .0005) and a residual small bowel length less than 50% of the original length (exp(B) = 26.84; P < .0005) were the only 2 variables in a logistic regression analysis found to be independently associated with the development of SBS.
CONCLUSION: This cohort study clearly illustrates the tremendous morbidity experienced by infants with SBS relative to other surgical neonates. Accurate estimates of the morbidity associated with SBS enables clinicians to appropriately counsel parents, allocate resources and initiate therapeutic trials.

Entities:  

Mesh:

Year:  2005        PMID: 15937809     DOI: 10.1016/j.jpedsurg.2005.01.037

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  42 in total

1.  Serial transverse enteroplasty for management of refractory D-lactic acidosis in short-bowel syndrome.

Authors:  Biren P Modi; Monica Langer; Christopher Duggan; Heung Bae Kim; Tom Jaksic
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-09       Impact factor: 2.839

2.  Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.

Authors:  Andreas Vegge; Thomas Thymann; Pernille Lund; Barbara Stoll; Stine B Bering; Bolette Hartmann; Jacob Jelsing; Niels Qvist; Douglas G Burrin; Palle B Jeppesen; Jens J Holst; Per T Sangild
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-13       Impact factor: 4.052

Review 3.  Nutritional support of infants with intestinal failure: something more than fishy is going on here!

Authors:  David Sigalet; Viona Lam; Dana Boctor; Mary Brindle
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

4.  Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury.

Authors:  Mark Puder; Clarissa Valim; Jonathan A Meisel; Hau D Le; Vincent E de Meijer; Elizabeth M Robinson; Jing Zhou; Christopher Duggan; Kathleen M Gura
Journal:  Ann Surg       Date:  2009-09       Impact factor: 12.969

Review 5.  Short bowel syndrome in the NICU.

Authors:  Sachin C Amin; Cleo Pappas; Hari Iyengar; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

6.  Risk factors for intestinal failure in infants with necrotizing enterocolitis: a Glaser Pediatric Research Network study.

Authors:  Debora Duro; Leslie A Kalish; Patrick Johnston; Tom Jaksic; Maggie McCarthy; Cami Martin; James C Y Dunn; Mary Brandt; Kerilyn K Nobuhara; Karl G Sylvester; R Lawrence Moss; Christopher Duggan
Journal:  J Pediatr       Date:  2010-05-06       Impact factor: 4.406

7.  An Observational Study of Smoflipid vs Intralipid on the Evolution of Intestinal Failure-Associated Liver Disease in Infants With Intestinal Failure.

Authors:  Christina Belza; John C Wales; Glenda Courtney-Martin; Nicole de Silva; Yaron Avitzur; Paul W Wales
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-08-25       Impact factor: 4.016

8.  Predictors of Enteral Autonomy in Children with Intestinal Failure: A Multicenter Cohort Study.

Authors:  Faraz A Khan; Robert H Squires; Heather J Litman; Jane Balint; Beth A Carter; Jeremy G Fisher; Simon P Horslen; Tom Jaksic; Samuel Kocoshis; J Andres Martinez; David Mercer; Susan Rhee; Jeffrey A Rudolph; Jason Soden; Debra Sudan; Riccardo A Superina; Daniel H Teitelbaum; Robert Venick; Paul W Wales; Christopher Duggan
Journal:  J Pediatr       Date:  2015-04-25       Impact factor: 4.406

9.  Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators.

Authors:  Brian T Kalish; Hau D Le; Jonathan M Fitzgerald; Samantha Wang; Kyle Seamon; Kathleen M Gura; Karsten Gronert; Mark Puder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

10.  Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months.

Authors:  Conrad R Cole; Nellie I Hansen; Rosemary D Higgins; Thomas R Ziegler; Barbara J Stoll
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.